It's Personal: How DNA-based therapies are transforming cancer care
Location: Willamette University - Hudson Hall
May 19, 2011 (one day)
Meets 5:30 PM-8:00 PM
Level: Free event - open to anyone
Status: This program is completed
A talk with internationally renowned cancer research physician Brian Druker, M.D., Director, OHSU Knight Cancer Institute
Dr. Druker helped revolutionize cancer treatment worldwide when he developed Gleevec®, a breakthrough drug that works by attacking a specific protein molecule linked to several types of cancer. He will discuss the future of personalized medicine – treatments that work with your individual genetic makeup.
The event will be held in Willamette University's Hudson Hall - located in Rogers Music Center - building 31 on this campus map:
900 State Street, Salem, OR 97301
- Community Health Fair starts at 5:30 pm - Over 20 exhibits from Mid-Valley cancer care experts and health organizations
- Dr. Druker speaks at 6:30 pm
- Light refreshments provided
- Parking is at Willamette University. No permits are needed. We will have volunteers/signage to direct people to Hudson Hall.
- Registration is encouraged but not required.
Instructor -- Brian Druker MD
Brian J. Druker (born 1955) is a physician-scientist at the Oregon Health & Science University. He is the director of OHSU Knight Cancer Institute, JELD-WEN Chair of Leukemia Research, and professor of medicine. In 2009 he won the Lasker Clinical Award and the Meyenburg Cancer Research Prize for his influential work in the development of STI571, commonly known as Gleevec, for the treatment of Chronic Myeloid Leukemia (CML).
Dr. Druker earned both his BS in chemistry and MD from the University of California, San Diego. He completed internship and residency in Internal Medicine at Barnes Hospital, Washington University School of Medicine in St. Louis from 1981 to 1984. He was a fellow in Medical Oncology at Dana-Farber Cancer Institute, Harvard Medical School from 1984 to 1987.